REIG JOFRE submits results note on third quarter of 2022
REIG JOFRE grew by 13% in revenues and by 6% in EBITDA in the first nine months of the year
REIG JOFRE closes with 195 million in accumulated revenue in the third quarter. The antibiotics market is recovering, the new injectable products plant has begun production and consumer products are showing solid growth.
At the end of September, REIG JOFRE had achieved €195 million in sales, a 13% increase over the same period of the previous year. The strong growth in Consumer Healthcare sales continues, production has increased at the new plant in Barcelona and the demand for antibiotics manufactured at the plant in Toledo has fully recovered. EBITDA grew by 6%, reaching €21.2 million and confirms the first half’s progress.
The Pharmaceutical Technologies unit, dedicated to injectable products and antibiotics, has continued to grow to double digits. The Speciality Pharmacare unit, focused on prescription products, accelerated the growth achieved in the first semester and Consumer Healthcare, the consumer products unit, had the highest percentage growth, in both the FORTE PHARMA brand, in the French, Belgian and Spanish markets, as well as in OTC products.